1 A prospective randomised trial was conducted to compare aminoglycoside dose prediction based on individually measured pharmacokinetic data, with dosage based on physician intuition. 2 After 2 days of therapy more patients in the pharmacokinetic group had achieved both peak (6-10 mg l-l) and trough (1-2 mg l-1) target plasma concentrations (P = 0.007), peaks alone (P = 0.01) and troughs alone (P = 0.01). Their mean (s.e. mean) peak concentration was 6.49 ± 0.39 mg 1-1 compared with 4.27 ± 0.52 mg 1-1 in the control group (P = 0.001), with trough concentrations of 1.44 ± 0.22 mg F-1 and 0.94 ± 0.21 mg F' respectively (P = 0.054). 3 After 5 days of therapy, peak and trough concentrations were still significantly higher in the pharmacokinetic group despite empirical dose adjustment (P = 0.01 and P = 0.013 respectively). 4 The mean (s.e. mean) daily dose of aminoglycoside was higher in the computer group (312 ± 17 mg vs 203 ± 13 mg, P = 0.001). 5 These findings suggest that dose estimation based on measured pharmacokinetic parameters is superior at achieving target plasma drug concentrations.